SCYNEXIS, Inc. Company profile
About SCYNEXIS Inc
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous oral agent for multiple fungal indications in both the community and hospital settings. It has received the acceptance letter from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). The FDA has conditionally approved Brexafemme as the brand name for oral ibrexafungerp for vaginal yeast infections. It is also continuing late-stage clinical development for the prevention of recurrent VVC, as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.
Financial summary
BRIEF: For the nine months ended 30 September 2021, SCYNEXIS Inc revenues increased from $0K to $12.6M. Net loss decreased 71% to $3.6M. Revenues reflect Revenue increase from $0K to $12.1M. Lower net loss reflects Warrant liabilities fair value adjustmen increase from $16.1M to $35.4M (income), Research and development - Balancing decrease of 40% to $15.6M (expense), Other expense decrease from $622K (expense) to $0K.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)